Clinical trials: Oligohydramnios
Fetal Membranes, Premature Rupture, Preterm Premature Rupture of the Membranes
PPROM Registry (Preterm Premature Rupture of Membranes)
Preterm Premature Rupture of Membranes (PPROM) before 37 weeks of pregnancy is responsible for 40% of preterm births in the United States.
- Conditions
- Fetal Membranes, Premature Rupture, Preterm Premature Rupture of the Membranes, Oligohydramnios, Premature Birth
- Trial name
- NCT02997345
- Testing
- There is no intervention associated with this study.
- Where
- United States
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- American Alliance for pProm Support
Oligohydramnios
Low Sodium Diet in Oligohydramnios Assigned for Conservative Management
The investigators want to examine whether low salt diet can increase the amniotic fluid index in patients diagnosed with oligohydramnios and assigned for conservative management. A randomized controlled trial
- Trial name
- NCT03815968
- Testing
- low sodium diet
- Where
- Israel
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Wolfson Medical Center
Autosomal Recessive Polycystic Kidney Disease (ARPKD)
A Study to See if Tolvaptan Can Delay Dialysis in Infants and Children Who at Enrollment Are 28 Days to Less Than 12 Weeks Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)
The primary objective of this study is to evaluate the effect of tolvaptan on the need for renal replacement therapy in pediatric subjects with autosomal recessive polycystic kidney disease (ARPKD)
- Trial name
- NCT04786574
- Testing
- Tolvaptan (OPC-41061)
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Abnormality in Fetal Heart Rate or Rhythm, Ultrasound
Uterine, Fetal Cerebral Doppler and Oligohydramnios to Predict Abnormal Heart Rate Tracings in Postterm Pregnancies
Objective: To estimate the value of uterine, fetal cerebral Doppler and oligohydramnios to predict abnormal fetal heart rate tracings in pregnancies at or beyond 41 weeks
- Conditions
- Abnormality in Fetal Heart Rate or Rhythm, Ultrasound, Late Pregnancy
- Trial name
- NCT03703037
- Testing
- Ultrasound and Doppler ultrasound
- Where
- Mexico
- Volunteers
- 227 people, healthy volunteers welcome
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
Autosomal Recessive Polycystic Kidney (ARPKD)
A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)
To evaluate the pharmacodynamics and safety of tolvaptan in pediatric subjects with ARPKD
- Trial name
- NCT04782258
- Testing
- Tolvaptan Suspension, Tolvaptan Tablets
- Where
- 23 sites in United States, Belgium and 4 more
- Volunteers
- 20 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.